The RainDance ADMESeq Extended Screening Panel enables researchers to simultaneously interrogate 242 known pharmacokinetic and pharmacology genes. The panel leverages RainDance’s proprietary primer design pipeline to target greater than 98 percent of the exons to provide highly accurate, consistent, and reproducible results required in ADME research and for most FDA drug applications. Our team of experts is here to help you reach your project goals.

• Simultaneously sequence 242 key ADME genes, including:
• 44 membrane transporters
• 86 genes with FDA-approved drugs with pharmacogenomic information in their labels
• 42 of the VIP genes from the Pharmacogenomics Knowlegbase
• Whole genome + targeted array: Increased probe coverage in exons of over 400 cancer associated genes, including over 70 genes mostly associated with germline
• Variations 20 kb overall median probe spacing
• ~5.1 probes per exon in over 400 targeted genes

• Sequence Coverage: 20x coverage for >98% of the targeted regions
• Concordance with HapMap SNPs: >97% concordance to HapMap genotypes (n=16)
• Greater Uniformity: >90% base coverage within 0.2x of the mean

• Certified Service Provider for Illumina, Ion Torrent, Agilent, RainDance and Roche NimbleGen
• Collaborated on thousands of projects
• Consistently high quality data and robust analysis
• Cost-effective and fast turnaround times
• Initial project planning teleconferences with our scientific team
• MD and PhD scientists available for personalized scientific consultation and project management
• CAP accredited and CLIA certified reference laboratory

• RainDance Thunderstorm
• RainDance RDT 1000
• Illumina MiSeq
• Illumina HiSeq 2000
• Illumina Genome Analyzer IIx